| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 687.15M | 639.14M | 445.54M | 11.55M | 106.87M | 49.21M |
| Gross Profit | 404.58M | 415.29M | 273.01M | -67.21M | 24.62M | -30.39M |
| EBITDA | 269.56M | 240.18M | 152.80M | -141.61M | -83.86M | -140.97M |
| Net Income | -66.03M | -96.73M | -133.52M | -326.45M | -252.56M | -321.63M |
Balance Sheet | ||||||
| Total Assets | 2.82B | 2.99B | 3.24B | 3.59B | 3.32B | 3.04B |
| Cash, Cash Equivalents and Short-Term Investments | 99.45M | 127.63M | 228.04M | 509.52M | 499.29M | 575.22M |
| Total Debt | 2.07B | 2.18B | 2.35B | 2.45B | 2.10B | 1.60B |
| Total Liabilities | 2.23B | 2.34B | 2.51B | 2.72B | 2.37B | 1.78B |
| Stockholders Equity | 543.86M | 590.74M | 728.98M | 876.14M | 944.18M | 1.27B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 103.14M | -175.72M | -630.90M | -541.32M | -370.16M |
| Operating Cash Flow | 0.00 | 189.90M | -18.89M | -178.78M | -136.84M | -181.63M |
| Investing Cash Flow | 0.00 | -108.46M | -161.54M | -453.39M | -407.24M | -195.51M |
| Financing Cash Flow | 0.00 | -183.26M | -100.90M | 643.11M | 471.51M | 623.89M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $44.92B | 29.98 | 62.28% | 1.50% | 8.37% | 10.20% | |
69 Neutral | $209.49M | 3.91 | ― | ― | 4.03% | ― | |
63 Neutral | $9.82B | 233.52 | 2.25% | ― | 0.05% | -94.07% | |
62 Neutral | $12.92B | 27.40 | ― | 0.81% | -0.26% | -44.45% | |
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% | |
56 Neutral | $3.44B | 33.52 | ― | ― | 11.32% | ― | |
40 Neutral | $735.40M | ― | -11.41% | ― | 9.50% | 24.64% |
On November 28, 2025, Studio City International Holdings Limited released its quarterly report for Studio City Finance Limited, detailing financial performance for the three and nine months ending September 30, 2025. The report highlights the company’s financial condition, including the repayment of the 2025 Studio City Finance Notes in July 2025, and the extension of credit facilities, which are crucial for its operational liquidity and future growth. These financial maneuvers are indicative of Studio City’s strategic efforts to maintain robust financial health and competitive positioning in the Macau gaming and hospitality market.
Studio City International Holdings Limited reported its unaudited financial results for the third quarter of 2025, showing an increase in total operating revenues to $182.5 million from $174.6 million in the same quarter of 2024. This growth was driven by enhanced performance in mass market operations, leading to increased casino contract revenue. The company also noted a reduction in net loss and improved operating income compared to the previous year, reflecting a strategic focus on mass market gaming. Additionally, Studio City managed to reduce its total debt by $109.3 million through repayments funded by credit facilities and cash on hand, indicating a strengthened financial position.
Studio City International Holdings Limited announced that it will release its unaudited financial results for the third quarter of 2025 on November 6, 2025. This announcement is significant for stakeholders as it provides insights into the company’s financial performance and strategic positioning in the competitive gaming and resort industry in Macau.
On September 16, 2025, Studio City International Holdings Limited announced that its subsidiary, SCRS, entered into an agreement with iRad to operate a private hospital at the Studio City integrated resort. The agreement, effective from January 1, 2025, allows iRad to provide imaging and diagnostic services starting tentatively on October 1, 2025, until November 30, 2034, with options for renewal. This strategic move is part of the company’s commitment to supporting Macau’s healthcare industry and aligns with its broader operational goals.